Is UNCY or RLMD more profitable?

Relmada Therapeutics' return on equity of -71.22% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -134.69% -84.51% Relmada Therapeutics N/A -71.22% -64.46%

Is UNCY or NGNE more profitable?

Neurogene's return on equity of -37.88% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -134.69% -84.51% Neurogene N/A -37.88% -34.70%

Is UNCY or HELP more profitable?

Cybin's return on equity of -68.27% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -134.69% -84.51% Cybin N/A -68.27% -58.26%

Unicycive Therapeutics (UNCY) Competitors

$5.06 +0.05 (+0.90%)

As of 10:52 AM Eastern

Compare

UNCY vs. RLMD, PRME, NGNE, HELP, and ARVN

Should you buy Unicycive Therapeutics stock or one of its competitors? MarketBeat compares Unicycive Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Unicycive Therapeutics include Relmada Therapeutics (RLMD), Prime Medicine (PRME), Neurogene (NGNE), Cybin (HELP), and Arvinas (ARVN).

How does Unicycive Therapeutics compare to Relmada Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

In the previous week, Relmada Therapeutics had 9 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 9 mentions for Relmada Therapeutics and 0 mentions for Unicycive Therapeutics. Relmada Therapeutics' average media sentiment score of 1.29 beat Unicycive Therapeutics' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Relmada Therapeutics	Positive

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Unicycive Therapeutics has higher revenue and earnings than Relmada Therapeutics. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	203.61	-$26.56M	-$2.21	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$1.09	N/A

Unicycive Therapeutics currently has a consensus price target of $21.75, suggesting a potential upside of 330.27%. Relmada Therapeutics has a consensus price target of $12.00, suggesting a potential upside of 130.55%. Given Unicycive Therapeutics' higher probable upside, equities research analysts plainly believe Unicycive Therapeutics is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Relmada Therapeutics' return on equity of -71.22% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Relmada Therapeutics	N/A	-71.22%	-64.46%

Summary

Relmada Therapeutics beats Unicycive Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Prime Medicine currently has a consensus target price of $7.53, suggesting a potential upside of 161.96%. Unicycive Therapeutics has a consensus target price of $21.75, suggesting a potential upside of 330.27%. Given Unicycive Therapeutics' higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Prime Medicine has a beta of 2.31, meaning that its stock price is 131% more volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market.

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Unicycive Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Unicycive Therapeutics' return on equity of -134.69% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Unicycive Therapeutics	N/A	-134.69%	-84.51%

In the previous week, Prime Medicine had 4 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 4 mentions for Prime Medicine and 0 mentions for Unicycive Therapeutics. Prime Medicine's average media sentiment score of 0.81 beat Unicycive Therapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Prime Medicine	Positive
Unicycive Therapeutics	Neutral

Unicycive Therapeutics has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	112.16	-$201.14M	-$1.23	N/A
Unicycive Therapeutics	$680K	203.61	-$26.56M	-$2.21	N/A

Summary

Prime Medicine beats Unicycive Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Neurogene?

Unicycive Therapeutics (NASDAQ:UNCY) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations, risk and media sentiment.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 52.4% of Neurogene shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 11.7% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Unicycive Therapeutics presently has a consensus target price of $21.75, suggesting a potential upside of 330.27%. Neurogene has a consensus target price of $84.83, suggesting a potential upside of 156.37%. Given Unicycive Therapeutics' higher possible upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00

Unicycive Therapeutics has higher earnings, but lower revenue than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	203.61	-$26.56M	-$2.21	N/A
Neurogene	$930K	562.17	-$90.35M	-$4.55	N/A

Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

Neurogene's return on equity of -37.88% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Neurogene	N/A	-37.88%	-34.70%

In the previous week, Neurogene had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 2 mentions for Neurogene and 0 mentions for Unicycive Therapeutics. Neurogene's average media sentiment score of 1.16 beat Unicycive Therapeutics' score of 0.00 indicating that Neurogene is being referred to more favorably in the news media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Neurogene	Positive

Summary

Neurogene beats Unicycive Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Cybin?

Unicycive Therapeutics (NASDAQ:UNCY) and Cybin (NASDAQ:HELP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Cybin has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market.

Unicycive Therapeutics currently has a consensus price target of $21.75, suggesting a potential upside of 330.27%. Cybin has a consensus price target of $45.25, suggesting a potential upside of 486.06%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cybin's return on equity of -68.27% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Cybin	N/A	-68.27%	-58.26%

In the previous week, Cybin had 4 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 4 mentions for Cybin and 0 mentions for Unicycive Therapeutics. Cybin's average media sentiment score of 0.73 beat Unicycive Therapeutics' score of 0.00 indicating that Cybin is being referred to more favorably in the news media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Cybin	Positive

Unicycive Therapeutics has higher revenue and earnings than Cybin. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	203.61	-$26.56M	-$2.21	N/A
Cybin	N/A	N/A	-$148M	-$4.23	N/A

Summary

Cybin beats Unicycive Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Unicycive Therapeutics compare to Arvinas?

Unicycive Therapeutics (NASDAQ:UNCY) and Arvinas (NASDAQ:ARVN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

Unicycive Therapeutics currently has a consensus target price of $21.75, indicating a potential upside of 330.27%. Arvinas has a consensus target price of $15.42, indicating a potential upside of 94.16%. Given Unicycive Therapeutics' higher probable upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Arvinas.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Arvinas	2 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.46

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 7.3% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Unicycive Therapeutics has a net margin of 0.00% compared to Arvinas' net margin of -247.54%. Arvinas' return on equity of -44.38% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Arvinas	-247.54%	-44.38%	-28.38%

In the previous week, Arvinas had 2 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 2 mentions for Arvinas and 0 mentions for Unicycive Therapeutics. Arvinas' average media sentiment score of 0.60 beat Unicycive Therapeutics' score of 0.00 indicating that Arvinas is being referred to more favorably in the news media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Arvinas	Positive

Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.74, suggesting that its share price is 74% more volatile than the broader market.

Unicycive Therapeutics has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	203.61	-$26.56M	-$2.21	N/A
Arvinas	$89.40M	5.73	-$80.80M	-$3.32	N/A

Summary

Arvinas beats Unicycive Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Unicycive Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UNCY vs. The Competition

Export

Metric	Unicycive Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$138.24M	$11.49B	$6.81B	$12.55B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-2.28	796.38	282.12	24.83
Price / Sales	203.61	749.10	573.08	78.59
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	3.59	10.32	11.02	6.15
Net Income	-$26.56M	$2.81B	$3.49B	$347.61M
7 Day Performance	-1.46%	2.14%	0.47%	1.17%
1 Month Performance	-11.78%	-1.98%	-4.24%	-3.46%
1 Year Performance	20.36%	157.82%	62.63%	19.43%

Unicycive Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UNCY Unicycive Therapeutics	2.2932 of 5 stars	$5.06 +0.9%	$21.75 +330.3%	+19.3%	$138.24M	$680K	N/A	9
RLMD Relmada Therapeutics	2.3194 of 5 stars	$5.15 -1.0%	$12.00 +133.1%	+799.4%	$539.97M	N/A	N/A	10	Positive News Upcoming Earnings
PRME Prime Medicine	3.414 of 5 stars	$2.98 -1.2%	$7.53 +153.2%	N/A	$537.53M	$4.63M	N/A	N/A	News Coverage
NGNE Neurogene	3.4231 of 5 stars	$33.66 -2.8%	$84.83 +152.1%	+51.0%	$534.59M	$930K	N/A	90	News Coverage Positive News Upcoming Earnings
HELP Cybin	2.3515 of 5 stars	$7.50 -2.5%	$45.25 +503.0%	N/A	$524.75M	N/A	N/A	50	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UNCY) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. RLMD, PRME, NGNE, HELP, and ARVN

How does Unicycive Therapeutics compare to Relmada Therapeutics?

Summary

How does Unicycive Therapeutics compare to Prime Medicine?

Summary

How does Unicycive Therapeutics compare to Neurogene?

Summary

How does Unicycive Therapeutics compare to Cybin?

Summary

How does Unicycive Therapeutics compare to Arvinas?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Unicycive Therapeutics (UNCY) Competitors

UNCY vs. RLMD, PRME, NGNE, HELP, and ARVN

How does Unicycive Therapeutics compare to Relmada Therapeutics?

Does the media favor UNCY or RLMD?

Do insiders and institutionals hold more shares of UNCY or RLMD?

Which has more volatility & risk, UNCY or RLMD?

Which has stronger earnings and valuation, UNCY or RLMD?

Do analysts recommend UNCY or RLMD?

Is UNCY or RLMD more profitable?

Summary

How does Unicycive Therapeutics compare to Prime Medicine?

Do analysts recommend PRME or UNCY?

Which has more risk and volatility, PRME or UNCY?

Do insiders & institutionals hold more shares of PRME or UNCY?

Is PRME or UNCY more profitable?

Does the media prefer PRME or UNCY?

Which has stronger valuation and earnings, PRME or UNCY?

Summary

How does Unicycive Therapeutics compare to Neurogene?

Do institutionals & insiders hold more shares of UNCY or NGNE?

Do analysts rate UNCY or NGNE?

Which has preferable valuation and earnings, UNCY or NGNE?

Which has more volatility and risk, UNCY or NGNE?

Is UNCY or NGNE more profitable?

Does the media favor UNCY or NGNE?

Summary

How does Unicycive Therapeutics compare to Cybin?

Do institutionals & insiders hold more shares of UNCY or HELP?

Which has more risk and volatility, UNCY or HELP?

Do analysts rate UNCY or HELP?

Is UNCY or HELP more profitable?

Does the media prefer UNCY or HELP?

Which has preferable valuation & earnings, UNCY or HELP?

Summary

How does Unicycive Therapeutics compare to Arvinas?

Do analysts prefer UNCY or ARVN?

Do institutionals and insiders believe in UNCY or ARVN?

Is UNCY or ARVN more profitable?

Does the media prefer UNCY or ARVN?

Which has more risk and volatility, UNCY or ARVN?

Which has stronger earnings and valuation, UNCY or ARVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UNCY vs. The Competition

Unicycive Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools